Schwab Andrew J.

CIK 000159854925 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001598549

Recent Transactions

50 trades

Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2026-02-06+35,000→ 35,000 total
Award
Camp4 Therapeutics Corp$CAMP
Common Stock
2025-09-11$1.53/sh+2,941,176→ 2,941,176 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-22$3.42/sh−6,470→ 57,493 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-22$3.42/sh−163,979→ 1,457,064 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-21$3.57/sh−58,642→ 1,621,043 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-21$3.57/sh−2,314→ 63,963 total
Award
Camp4 Therapeutics Corp$CAMP
Stock Option (Right to Buy)
2025-06-25+9,000→ 9,000 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2025-02-24+35,000→ 35,000 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2024-10-28+70,000→ 70,000 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series B Preferred Stock
2024-10-15−4,244,770→ 0 total
Conversion
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15+1,337,592→ 1,337,592 total
Conversion
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15+302,770→ 302,770 total
Purchase
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15$11.00/sh+909,090→ 2,625,145 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series B Preferred Stock
2024-10-15−3,395,816→ 0 total
Conversion
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15+378,463→ 1,716,055 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series A Prime Preferred Stock
2024-10-15−15,002,166→ 0 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−2,000→ 1,679,685 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−11,758→ 8,167,206 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−79→ 66,277 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−1,440→ 66,356 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−214,556→ 8,178,964 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−36,504→ 1,681,685 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2024-03-13$10.00/sh+450,000→ 8,393,520 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2024-02-29+35,000→ 35,000 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2024-01-31$2.31/sh+5,206,074→ 7,943,520 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2023-11-06+14,110→ 20,001 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2023-08-25+1,472,692→ 1,472,692 total
Award
Skye Bioscience, Inc.$SKYE
Warrant (Right to Buy)
2023-08-18+426,348,120→ 426,348,120 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2023-08-18+267,602,039→ 267,602,039 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2023-08-18$0.01/sh+684,361,447→ 684,361,447 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2023-08-18$0.01/sh+6,389,921→ 16,948,799 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2023-08-18+10,558,878→ 10,558,878 total
Award
Skye Bioscience, Inc.$SKYE
Common Stock
2023-08-18$0.01/sh+161,944,872→ 429,546,911 total
Award
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-02-23+4,838,092→ 4,838,092 total
Award
Enliven Therapeutics, Inc.$ELVN
Stock Option (right to buy)
2023-02-23+27,567→ 27,567 total
Award
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-02-23+960,383→ 960,383 total
Award
Pear Therapeutics, Inc.
Class A Common Stock
2021-12-03+14,648,641→ 14,648,641 total
Award
Pear Therapeutics, Inc.
Class A Common Stock
2021-12-03+610,361→ 610,361 total
Award
Pear Therapeutics, Inc.
Class A Common Stock
2021-12-03+3,172,769→ 3,172,769 total
Award
Pear Therapeutics, Inc.
Class A Common Stock
2021-12-03$10.00/sh+200,000→ 3,372,769 total
Other
5:01 Acquisition Corp.
Class B Common Stock
2020-11-30−235,932→ 1,944,068 total
Other
5:01 Acquisition Corp.
Class B Common Stock
2020-11-17−30,000→ 2,180,000 total
Other
5:01 Acquisition Corp.
Class A Common Stock
2020-11-12$10.00/sh+5,126→ 365,126 total
Other
5:01 Acquisition Corp.
Class A Common Stock
2020-10-16$10.00/sh+360,000→ 360,000 total
Other
5:01 Acquisition Corp.
Class B Common Stock
2020-10-16−90,000→ 2,210,000 total
Purchase
scPharmaceuticals Inc.$SCPH
Common Stock
2020-05-26$8.65/sh+578,034→ 578,034 total
Award
Flexion Therapeutics Inc
Stock option (right to buy)
2014-03-03+9,000→ 9,000 total
Conversion
Flexion Therapeutics Inc
Series B Preferred Stock
2014-02-18−1,693,249→ 0 total
Conversion
Flexion Therapeutics Inc
Series A Preferred Stock
2014-02-18−10,499,946→ 0 total
Conversion
Flexion Therapeutics Inc
Common Stock
2014-02-18+208,272→ 1,512,076 total

Companies

Recent Filings

Address

C/O 5AM VENTURE MANAGEMENT, LLC 4 EMBARCADERO CENTER, SUITE 3110

SAN FRANCISCO, CA, 94111

View on SEC.gov